Evidence map›Paper›PMID 31697716›Full record

ArticlePloS one2019

Tissue-type plasminogen activator selectively inhibits multiple toll-like receptors in CSF-1-differentiated macrophages.

Lipsa Das, Pardis Azmoon, Michael A Banki, Elisabetta Mantuano, Steven L Gonias

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.7field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. A Soluble PrPJournal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  8. Review
  9. α1-Antitrypsin derived SP16 peptide demonstrates efficacy in rodent models of acute and neuropathic pain.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2022
    Article
  10. Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Lipsa DasDepartment of Pathology, University of California San Diego, La Jolla, California, United States of America.
Pardis AzmoonDepartment of Pathology, University of California San Diego, La Jolla, California, United States of America.
Michael A BankiDepartment of Pathology, University of California San Diego, La Jolla, California, United States of America.
Elisabetta MantuanoDepartment of Pathology, University of California San Diego, La Jolla, California, United States of America.ORCID 0000-0001-5728-9261
Steven L GoniasDepartment of Pathology, University of California San Diego, La Jolla, California, United States of America.ORCID 0000-0003-0843-4607
University of California San Diego · US

Funding

Regulation of Inflammation by the Fibrinolytic SystemR01HL136395 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GONIAS, STEVEN L. · 2017 to 2025
$3.5M
Schwann Cell NMDA Receptor in PNS InjuryR01NS097590 · NINDS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAMPANA, WENDY M., GONIAS, STEVEN L. · 2017 to 2020
$1.4M
NHLBI NIH HHS R01 HL136395NINDS NIH HHS R01 NS097590
6 · The paper itself

Abstract

Tissue-type plasminogen activator (tPA) is a major activator of fibrinolysis, which also attenuates the pro-inflammatory activity of lipopolysaccharide (LPS) in bone marrow-derived macrophages (BMDMs) and in vivo in mice. The activity of tPA as an LPS response modifier is independent of its proteinase activity and instead, dependent on the N-methyl-D-aspartate Receptor (NMDA-R), which is expressed by BMDMs. The major Toll-like receptor (TLR) for LPS is TLR4. Herein, we show that enzymatically-inactive (EI) tPA blocks the response of mouse BMDMs to selective TLR2 and TLR9 agonists, rapidly reversing IκBα phosphorylation and inhibiting expression of TNFα, CCL2, interleukin-1β, and interleukin-6. The activity of EI-tPA was replicated by activated α2-macroglobulin, which like EI-tPA, signals through an NMDA-R-dependent pathway. EI-tPA failed to inhibit cytokine expression by BMDMs in response to agonists that target the Pattern Recognition Receptors (PRRs), NOD1 and NOD2, providing evidence for specificity in the function of EI-tPA. Macrophages isolated from the peritoneal space (PMs), without adding eliciting agents, expressed decreased levels of cell-surface NMDA-R compared with BMDMs. These cells were unresponsive to EI-tPA in the presence of LPS. However, when PMs were treated with CSF-1, the abundance of cell-surface NMDA-R increased and the ability of EI-tPA to neutralize the response to LPS was established. We conclude that the anti-inflammatory activity of EI-tPA is selective for TLRs but not all PRRs. The ability of macrophages to respond to EI-tPA depends on the availability of cell surface NMDA-R, which may be macrophage differentiation-state dependent.

Indexed as

AnimalsCell DifferentiationCytokinesHumansInflammationInflammation MediatorsLipopolysaccharidesMacrophage Colony-Stimulating FactorMacrophagesMice, Inbred C57BLNeutralization TestsNod1 Signaling Adaptor ProteinNod2 Signaling Adaptor ProteinReceptors, N-Methyl-D-AspartateTissue Plasminogen ActivatorToll-Like ReceptorsCytokinesInflammation MediatorsLipopolysaccharidesMacrophage Colony-Stimulating FactorNod1 Signaling Adaptor ProteinNod2 Signaling Adaptor ProteinReceptors, N-Methyl-D-AspartateTissue Plasminogen ActivatorToll-Like Receptors

Identifiers

PMID31697716
PMCPMC6837328
OpenAlexW2986992147

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.